Tech Company Financing Transactions
Clene Nanomedicine Funding Round
Private investors and Kensington Capital Partners participated in a $4 million funding round for Clene Nanomedicine. The round was announced on 9/21/2026.
Transaction Overview
Company Name
Announced On
9/21/2026
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Undisclosed
Investors
private investors (Lead Investor) (David Matlin)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6550 South Millrock Dr. G50
Salt Lake City, UT 84121
USA
Salt Lake City, UT 84121
USA
Phone
Website
Email Address
Overview
Clene Nanomedicine, Inc. is a privately-held, clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Etherington
Chief Financial Officer
Matthew Gardner
Chief Medical Officer
Robert Glanzman
Chief Scientific Officer
Mark Mortenson
VP - Bus. Development
Michael Hotchkin
Browse more venture capital transactions:
Prev: 9/21/2026: Carro venture capital transaction
Next: 9/21/2026: Metris Energy venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs